AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Antimicrobial, Stimuli-responsive Polysaccharide

Technology Benefits
Reduced toxicity and similar efficacy in reducing bacterial growth compared to native chitosanCan be selectively returned to native chitosan at low pH to target specific areas
Technology Application
· Broad spectrum nanoantibiotics
Detailed Technology Description
State of the art antimicrobials have up to 14 years of efficacy before resistance develops in microbes, after which a new antimicrobial compound must be researched and developed. The process can take years and millions of dollars, which has led many pharmaceutical companies to reduce investment in new antibiotics. Nanoantibiotics have recently gained attention as a therapeutic strategy. They are nanomaterials that have inherent antimicrobial activity or improve efficacy and safety of antibiotics administration. Nanoantibiotics have different attack mechanisms that result in advantages over conventional antibiotics. Chitosan is a natural material derived from the shells of shrimp and other crustaceans which have shown promise as a nanoantibiotic. However, native chitosan has low solubility at biological pH and therefore low therapeutic potential against the microbes. UCI researchers have developed a way to make acid-transforming chitosan (ATC) to enhance solubility and lower toxicity, while sustaining the bioactivity. The researchers believe that the method can create a chitosan that targets various locations in the body.
Others

State Of Development

Various formulations have been made and in vitro and in vivo studies have been performed to understand the appropriate pharmacological doses.


Tech ID/UC Case

28937/2018-062-0


Related Cases

2018-062-0

*Abstract

State of the art antimicrobial therapeutics, while effective and promising, remain only short-term solutions to the overall challenge of drug-resistant microbes. UCI researchers have developed a chitosan-based nanoantibiotic that is non-toxic and carries potential for broad spectrum use.

*Principal Investigator

Name: Julius Edson

Department:


Name: Young Jik Kwon

Department:

Country/Region
USA

For more information, please click Here
Mobile Device